ALKS
Alkermes plc
NASDAQ · Healthcare · Biotechnology · IE
$46.10
−1.66%0
Insider buys (3m)
11
Insider sells (3m)
-$4.3M
Net value (3m)
+8.8%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Sep 3, 2026 | Gaffin David Joseph · officer: EVP, CLO, Alkermes, Inc. | Sale | 2,034 | $48 |
| Sep 1, 2026 | Hopkinson Craig C. · officer: EVP R&D, Chief Medical Officer | Sale | 9,000 | $47 |
| Sep 1, 2026 | Hopkinson Craig C. · officer: EVP R&D, Chief Medical Officer | M-Exempt | 5,000 | $25 |
| Aug 17, 2026 | Nichols Christian Todd · officer: SVP, Chief Commercial Officer | Sale | 6,912 | $49 |
| Aug 17, 2026 | Nichols Christian Todd · officer: SVP, Chief Commercial Officer | Sale | 664 | $50 |
| Aug 7, 2026 | Jackson Blair Curtis · director, officer: President & CEO, Alkermes plc | A-Award | 124,305 | $50 |
| Aug 7, 2026 | Jackson Blair Curtis · director, officer: President & CEO, Alkermes plc | A-Award | 93,229 | $50 |
| Aug 3, 2026 | Hopkinson Craig C. · officer: EVP R&D, Chief Medical Officer | M-Exempt | 104 | $19 |
| Aug 3, 2026 | snyderman nancy lynn MD · director | M-Exempt | 16,524 | $47 |
| Aug 3, 2026 | snyderman nancy lynn MD · director | M-Exempt | 27,948 | $47 |
| Aug 3, 2026 | snyderman nancy lynn MD · director | Sale | 44,472 | $50 |
| Aug 3, 2026 | Hopkinson Craig C. · officer: EVP R&D, Chief Medical Officer | M-Exempt | 4,896 | $25 |
| Aug 3, 2026 | Gaffin David Joseph · officer: EVP, CLO, Alkermes, Inc. | Sale | 2,034 | $49 |
| Aug 3, 2026 | Hopkinson Craig C. · officer: EVP R&D, Chief Medical Officer | Sale | 9,000 | $49 |
| Jul 6, 2026 | Gaffin David Joseph · officer: EVP, CLO, Alkermes, Inc. | Sale | 2,034 | $54 |
| Jul 1, 2026 | Hopkinson Craig C. · officer: EVP R&D, Chief Medical Officer | M-Exempt | 5,000 | $19 |
| Jul 1, 2026 | Hopkinson Craig C. · officer: EVP R&D, Chief Medical Officer | Sale | 700 | $52 |
| Jul 1, 2026 | Hopkinson Craig C. · officer: EVP R&D, Chief Medical Officer | Sale | 8,300 | $51 |
| Jun 12, 2026 | Wright Christopher I · director | Sale | 2,000 | $45 |
| Jun 4, 2026 | Gaffin David Joseph · officer: EVP, CLO, Alkermes, Inc. | Sale | 2,034 | $43 |
| Jun 1, 2026 | Hopkinson Craig C. · officer: EVP R&D, Chief Medical Officer | M-Exempt | 5,000 | $19 |
| Jun 1, 2026 | Hopkinson Craig C. · officer: EVP R&D, Chief Medical Officer | Sale | 9,000 | $42 |
| May 29, 2026 | Parisi Samuel Joseph · officer: VP, Finance (Interim PAO) | M-Exempt | 3,392 | $20 |
| May 29, 2026 | Parisi Samuel Joseph · officer: VP, Finance (Interim PAO) | Sale | 16,217 | $42 |
| May 29, 2026 | Parisi Samuel Joseph · officer: VP, Finance (Interim PAO) | M-Exempt | 12,825 | $19 |
| May 22, 2026 | Cooke Shane · director | A-Award | 11,538 | $37 |
| May 22, 2026 | LAURENCIN CATO T · director | M-Exempt | 6,142 | $0.00 |
| May 22, 2026 | MCKEON BRIAN P · director | A-Award | 11,538 | $37 |
| May 22, 2026 | LAURENCIN CATO T · director | A-Award | 11,538 | $37 |
| May 22, 2026 | LAURENCIN CATO T · director | F-InKind | 1,475 | $37 |
Institutional positioning
13F filings over the trailing two quarters
New 168Increased 264Reduced 290Sold out 53
| Filer | Action | Shares | Filed |
|---|---|---|---|
| BlackRock, Inc. | Increased | 29,235,739 | Aug 7, 2026 |
| BLACKROCK, INC. | Increased | 28,314,410 | May 13, 2026 |
| BAKER BROS. ADVISORS LP | Unchanged | 10,012,267 | Aug 14, 2026 |
| BAKER BROS. ADVISORS LP | Unchanged | 10,012,267 | May 15, 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | New Position | 9,511,112 | May 8, 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | Reduced | 9,490,818 | Aug 13, 2026 |
| STATE STREET CORP | Reduced | 9,465,286 | May 15, 2026 |
| STATE STREET CORP | Reduced | 9,160,575 | Aug 7, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 7,515,025 | Aug 13, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 7,427,397 | May 15, 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ | Increased | 6,737,328 | Aug 14, 2026 |
| RENAISSANCE TECHNOLOGIES LLC | Increased | 6,460,928 | Aug 13, 2026 |
| RENAISSANCE TECHNOLOGIES LLC | Reduced | 6,160,428 | May 14, 2026 |
| AMERICAN CENTURY COMPANIES INC | Increased | 6,072,103 | May 15, 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ | Reduced | 4,664,576 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Sep 3, 2026